Examples of 'dabigatran etexilate' in a sentence
Meaning of "dabigatran etexilate"
dabigatran etexilate: A medication used to prevent blood clots and reduce the risk of stroke in patients with certain heart rhythm disorders
Show more definitions
- An oral prodrug that is hydrolyzed to the competitive and reversible direct thrombin inhibitor dabigatran.
How to use "dabigatran etexilate" in a sentence
Basic
Advanced
dabigatran etexilate
Prevent heart conditions or strokes dabigatran etexilate.
Dabigatran etexilate concentrations may increase.
Patients can stay on dabigatran etexilate while being cardioverted.
Dabigatran etexilate should be temporarily discontinued.
Pradaxa contains the active substance dabigatran etexilate.
Interactions linked to dabigatran etexilate and dabigatran metabolic profile.
Pradaxa is a medicine containing the active substance dabigatran etexilate.
Dabigatran etexilate has not been clinically studied together with tacrolimus.
Known hypersensitivity to dabigatran or dabigatran etexilate or to one of the excipients.
Therefore surgical interventions may require the temporary discontinuation of dabigatran etexilate.
The combination of rilpivirine and dabigatran etexilate should be used with caution.
Pradaxa is a medicine that contains the active substance dabigatran etexilate.
Dabigatran etexilate is a small molecule prodrug which does not exhibit any pharmacological activity.
Pradaxa is a medicine which contains the active substance dabigatran etexilate.
Dabigatran etexilate mesylate is an anticoagulant drug from the class of the direct thrombin inhibitors.
See also
Bleeding can occur at any site during therapy with dabigatran etexilate.
Both dose strengths of dabigatran etexilate had also a statistically significant lower total bleed rate.
Viekirax without dasabuvir may increase the plasma concentrations of dabigatran etexilate.
The combination of Eviplera and dabigatran etexilate should be used with caution.
Women of childbearing potential should avoid pregnancy during treatment with dabigatran etexilate.
The combination of Juluca and dabigatran etexilate should be used with caution.
The present invention provides a bismesylate salt of Dabigatran etexilate.
Crystalline forms of Dabigatran etexilate bismesylate include different polymorphic crystalline forms.
There are limited amount of data from the use of dabigatran etexilate in pregnant women.
The above Dabigatran etexilate bismesylate of the present invention can be amorphous or crystalline.
In one embodiment the invention encompasses Dabigatran etexilate bismesylate salt.
When dissolved, dabigatran etexilate methanesulphonateis dissolved.
With improving monitoring of INR the observed benefits of dabigatran etexilate compared to warfarin diminish.
The dabigatran etexilate bismesylate salt of claim 1, wherein the salt is crystalline.
The present invention also provides a pharmaceutical composition comprising Dabigatran etexilate bismesylate salt.
The present invention provides Dabigatran etexilate bismesylate salt and its crystalline form.
Methadone ( used to treat narcotic withdrawal and dependence ) dabigatran etexilate anticoagulant.
Here, the comparison with dabigatran etexilate should be particularly emphasized.
Certain medicines used to prevent strokes and blood clots e.g. dabigatran etexilate.
Dabigatran, the active moiety of dabigatran etexilate mesilate, is persistent in the environment.
This includes all bleeding events, which occurred during dabigatran etexilate therapy.
Doses of dabigatran etexilate beyond those recommended, expose the patient to increased risk of bleeding.
Re-administration of dabigatran etexilate.
Dabigatran etexilate has a narrow therapeutic index and should be monitored, and dose reduction if required.
Hours after the idarucizumab infusion, re-administration of dabigatran etexilate resulted in expected anticoagulant activity.
Dabigatran etexilate used with p-glycoprotein inducers require monitoring of decreased levels and effects of dabigatran.
Therefore, the present invention relates to Dabigatran etexilate bismesylate.
Dabigatran etexilate dasabuvir + ombitasvir / paritaprevir / ritonavir may increase the plasma concentrations of dabigatran etexilate.
Your doctor has initiated treatment with Pradaxa ® dabigatran etexilate.
Dabigatran etexilate is a substrate for the efflux transporter P-gp.
Concomitant administration of the P-gp substrate dabigatran etexilate may result in increased dabigatran plasma concentrations.
Dabigatran etexilate mesylate is marketed under the trade name PRADAXA ® by Boehringer Ingelheim.
Background of the Invention Dabigatran etexilate mesylate has the chemical structure,.
Dabigatran etexilate Mechanism, Intestinal Pgp inhibition by paritaprevir and ritonavir.
Each hard capsule contains 75 mg dabigatran etexilate as mesilate.
You'll also be interested in:
Examples of using Dabigatran
Show more
The initial data on dabigatran were quite encouraging
Dabigatran prolongs aPTT without linear effect
Patients receiving dabigatran should be monitored appropriately
